CSF1R Modulation Therapy: Microglia Reset Protocol

Migration, Crosslink

📖

CSF1R Modulation Therapy: Microglia Reset Protocol

active

wiki page Created: 2026-04-02T07:19:35 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-ideas-csf1r-modulation-microglia-re

📖 Wiki Page

idea1879 wordssynced 2026-04-02

CSF1R Modulation Therapy: Microglia Reset Protocol

Overview

CSF1R (Colony Stimulating Factor 1 Receptor) Modulation Therapy represents a novel therapeutic strategy that exploits the unique biology of microglia—the brain's resident immune cells. By transiently inhibiting CSF1R signaling, this approach achieves controlled microglia depletion followed by repopulation with phenotypically "reset" microglia, reducing chronic neuroinflammation while preserving essential immune surveillance.[@elmore2014][@han2021]

This approach differs from complete microglial ablation by incorporating a repopulation phase after transient depletion, allowing for a "reset" of the microglial compartment to a more youthful, less inflammatory phenotype. The therapy is applicable across multiple neurodegenerative diseases including Alzheimer's Disease (AD), Parkinson's Disease (PD), and Amyotrophic Lateral Sclerosis (ALS).

Rationale

...

CSF1R Modulation Therapy: Microglia Reset Protocol

Overview

CSF1R (Colony Stimulating Factor 1 Receptor) Modulation Therapy represents a novel therapeutic strategy that exploits the unique biology of microglia—the brain's resident immune cells. By transiently inhibiting CSF1R signaling, this approach achieves controlled microglia depletion followed by repopulation with phenotypically "reset" microglia, reducing chronic neuroinflammation while preserving essential immune surveillance.[@elmore2014][@han2021]

This approach differs from complete microglial ablation by incorporating a repopulation phase after transient depletion, allowing for a "reset" of the microglial compartment to a more youthful, less inflammatory phenotype. The therapy is applicable across multiple neurodegenerative diseases including Alzheimer's Disease (AD), Parkinson's Disease (PD), and Amyotrophic Lateral Sclerosis (ALS).

Rationale

Chronic neuroinflammation is a hallmark of neurodegenerative diseases, with disease-associated microglia (DAM) contributing to neuronal loss[@kerenshaul2017]
CSF1R signaling is essential for microglial survival and proliferation—transient inhibition allows controlled depletion[@spangenberg2019]
Microglial repopulation after withdrawal results in a phenotypically naive microglial population with reduced inflammatory signatures[@elmore2018]
Clinical momentum: Multiple CSF1R inhibitors (PLX3397, PLX5622, BLZ945, JNJ-40346527) are in various stages of clinical development[@clinicaltrialsgov]
Combination potential: Can be combined with amyloid/target immunotherapy, autophagy inducers, or other anti-inflammatory approaches

Mechanistic Logic

Mermaid diagram (expand to render)

Key Mechanisms

Transient Depletion: 2-4 weeks of CSF1R inhibitor treatment depletes ~95% of brain microglia[@spangenberg2019]

Repopulation: Upon drug withdrawal, residual microglia proliferate rapidly, supplemented by bone marrow-derived progenitors[@elmore2018]

Phenotypic Reset: Repopulated microglia exhibit reduced DAM markers, lower cytokine production, and improved phagocytic function[@elmore2018]

Disease Modification: Reduced neuroinflammation may slow disease progression in AD, PD, and ALS models[@dagher2015][@baruch2015]

Rubric Scores

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 8 | Repopulation protocol is novel; inhibitors themselves are known but "reset" strategy is emerging |
| Mechanistic Rationale | 9 | Strong preclinical evidence for microglia reset; CSF1R biology well-validated[@spangenberg2019][@elmore2018] |
| Addresses Root Cause | 7 | Targets neuroinflammation—a key disease mechanism but not the primary proteinopathy |
| Delivery Feasibility | 7 | Brain-penetrant inhibitors exist (PLX5622, BLZ945); oral delivery possible[@clinicaltrialsgov] |
| Safety Plausibility | 7 | Known safety profile from oncology; CNS effects need characterization[@pexidartinib] |
| Combinability | 9 | Synergizes with immunotherapy, autophagy inducers, other anti-inflammatory approaches |
| Biomarker Availability | 6 | CSF1, IL-34, TREM2 ligands measurable; microglial imaging in development |
| De-risking Path | 8 | Multiple compounds in clinical trials; established preclinical models[@clinicaltrialsgov] |
| Multi-disease Potential | 9 | AD, PD, ALS, FTD, MS—all have microglial involvement[@dagher2015][@baruch2015][@martinezmuriana2016] |
| Patient Impact | 8 | Addresses a common pathway across many neurodegenerative conditions |

Total Score: 78/100

Drug Candidates

| Drug | Company | Stage | CSF1R Selectivity | Notes |
|------|---------|-------|-------------------|-------|
| PLX5622 | Plexxikon | Preclinical | High | Most studied; brain-penetrant[@spangenberg2019] |
| BLZ945 | Novartis | Preclinical | Very High | Excellent CNS penetration[@zhou2023] |
| PLX3397 (Pexidartinib) | Plexxikon/Daiichi Sankyo | Phase 1 | Moderate | FDA-approved for TGCT; CNS trials[@butowski2016] |
| JNJ-40346527 | Janssen | Phase 1 (ALS) | High | Completed safety study[@clinicaltrialsgov] |
| AXL-2009 | Axxonis | Phase 1 (AD) | High | Currently recruiting |

Preclinical Evidence

Alzheimer's Disease Models

5xFAD mice: PLX5622 treatment depletes microglia, reduces neuroinflammation, improves cognitive function despite increased amyloid plaques[@dagher2015]
APP/PS1 mice: Reduced plaque-associated microglia, improved synaptic function[@dagher2015]
Paradoxical plaque increase observed but compensated by improved neuronal function—suggests targeting downstream inflammation may be key

Parkinson's Disease Models

α-synuclein transgenic mice: PLX5622 reduces microglia, protects dopaminergic neurons, improves motor function[@baruch2015]
MPTP models: Reduced neuroinflammation and neuronal loss in substantia nigra[@baruch2015]

ALS Models

SOD1G93A mice: PLX5622 extends survival by ~20%, reduces microglial proliferation[@martinezmuriana2016]
TDP-43 models: Reduced microglial activation and motor neuron pathology[@martinezmuriana2016]

Clinical Trial Status

| Trial ID | Compound | Disease | Phase | Status | Sponsor |
|----------|----------|---------|-------|--------|---------|
| NCT04121247 | JNJ-40346527 | ALS | Phase 1 | Completed | Janssen |
| NCT05452326 | AXL-2009 | AD | Phase 1 | Recruiting | Axxonis |
| NCT04889066 | PLX3397 | Brain Cancer | Phase 1 | Ongoing | Daiichi Sankyo |

Safety Profile

Common Adverse Effects

| Adverse Event | Frequency | Severity | Management |
|---------------|-----------|----------|------------|
| Liver enzyme elevation | Common | Mild-Moderate | Monitor; reversible on discontinuation |
| Fatigue | Common | Mild | Usually self-limiting |
| Headache | Common | Mild | Self-limiting |
| Anemia | Common | Mild-Moderate | Monitor blood counts |
| Leukopenia | Common | Mild-Moderate | Usually reversible |

CNS-Specific Considerations

Peripheral immune effects: May affect peripheral macrophages—monitor for infections

Long-term depletion: Unknown effects of prolonged microglial absence

BBB penetration: Varies by compound—critical for CNS efficacy[@zhou2023]

Off-target effects: Some inhibitors target KIT, FLT3—potential for hematologic effects[@pexidartinib]

Contraindications

Immunocompromised patients
Active infections
Severe hepatic impairment

Comparison to Other Microglia-Targeting Approaches

| Approach | Mechanism | Stage | Advantages | Limitations |
|----------|-----------|-------|------------|-------------|
| CSF1R Modulation | Deplete + reset microglia | Preclinical/Phase 1 | Reversible; phenotypic reset | Requires treatment holiday |
| TREM2 Agonism | Enhance phagocytosis | Preclinical | Direct enhancement of clearance | Single target; less inflammatory |
| CD33 Inhibition | Block inhibitory signal | Preclinical | Oral delivery possible | Limited efficacy alone |
| TREM2 CAR-T | Engineered phagocytes | Preclinical | Targeted cell therapy | Complex delivery |

Combination Strategies

CSF1R modulation + amyloid immunotherapy: Deplete microglia before/after antibody treatment to enhance plaque clearance[@dagher2015]
CSF1R modulation + autophagy inducers: Combined neuroinflammation reduction and protein clearance
CSF1R modulation + neurotrophic factors: Support neuron survival during inflammatory reset
CSF1R modulation + exercise mimetics: Enhance microglial rejuvenation through multiple pathways

Actionable Next Steps

Lab Experiments

Microglia depletion-repopulation model: Test PLX3397 (Pexidartinib) or PLX5622 in 5xFAD and alpha-synuclein mouse models. Assess whether temporary depletion followed by repopulation leads to improved microglial phenotype and reduced pathology.

CSF1R agonist vs. antagonist comparison: Compare CSF1R agonism (CSF1, IL-34) vs. antagonism (PLX3397) in iPSC-derived microglia. Use single-cell RNA-seq to characterize state transitions.

Temporal dosing optimization: Test intermittent vs. continuous CSF1R modulation. Determine whether "pulse" dosing reduces pathology more effectively than chronic treatment.

Combination with TREM2 targeting: Test whether CSF1R modulation enhances response to TREM2 agonism. Use dual-treatment paradigm in mouse models.

Clinical Protocol Design

Patient stratification: Select participants with evidence of pathological microglial activation (elevated CSF YKL-40, GFAP, or PET ligand binding).

Dose-finding study: Test multiple dosing schedules of PLX3397 or PLX5622 (pulsed vs. continuous). Primary endpoint: change in CSF inflammatory markers.

Biomarker monitoring: Include longitudinal CSF YKL-40, NfL, p-tau, and PET imaging for microglial activation.

Repopulation assessment: Monitor for rebound microglial activation after treatment cessation.

Company Partnership Opportunities

Plexxikon/Daiichi Sankyo: Partner for PLX3397 (Turalio) development

Roche: Explore CSF1R antibody (lacnotuzumab) for CNS applications

Denali Therapeutics: Partner for BBB-penetrant CSF1R inhibitors

Implementation Roadmap

Phase 1: Preclinical Development (Months 1-12)

| Milestone | Timeline | Activities | Lead |
|-----------|----------|------------|------|
| Agonist/antagonist comparison | Months 1-4 | Test both approaches in AD/PD mouse models | Academic lab |
| Temporal dosing optimization | Months 3-8 | Determine optimal pulsing schedule | Academic lab |
| IND-enabling studies | Months 6-12 | GLP toxicology for lead compound | CRO |
| Regulatory pre-IND | Months 10-12 | Prepare FDA/EMA package | Regulatory affairs |

Budget Estimate: $3-5M

Phase 2a: Phase 1 Clinical Trial (Months 13-24)

| Milestone | Timeline | Activities | Lead |
|-----------|----------|------------|------|
| Trial design | Months 13-15 | Single ascending dose, healthy volunteers + early AD/PD | Clinical team |
| Site selection | Months 14-16 | Identify 3-4 sites with neuroimaging capabilities | Operations |
| Trial execution | Months 17-24 | Enrollment, dosing, safety monitoring | Sites |

Budget Estimate: $5-8M

Phase 2b: Phase 2 Trial (Months 25-42)

| Milestone | Timeline | Activities | Lead |
|-----------|----------|------------|------|
| Phase 2 design | Months 25-27 | Biomarker-driven, N=100-150 AD/PD patients | Clinical team |
| Patient enrollment | Months 28-36 | Multi-site enrollment | Sites |
| Data analysis | Months 37-42 | Inflammatory biomarkers, cognitive endpoints | Biostatistics |

Budget Estimate: $15-20M

Key Academic Centers for Development

UCLA Center for Healthier Aging - Microglia imaging
Mayo Clinic Rochester - Neuroinflammation biomarkers
Banner Sun Health Research Institute - AD clinical trials
University of Pennsylvania - PET imaging of microglia

Potential Industry Partners

Plexxikon/Daiichi Sankyo (PLX3397)
Denali Therapeutics (BBB-penetrant inhibitors)
Roche (lacnotuzumab)
Acumen Pharmaceuticals (TREM2 programs)

Risk Assessment

| Risk | Likelihood | Impact | Mitigation |
|------|------------|--------|------------|
| Excessive microglial depletion | Medium | High | Test multiple doses, careful monitoring |
| Immune system compromise | Medium | High | Exclude immunocompromised, monitor infections |
| Insufficient target engagement | Medium | Medium | Use PET ligand for occupancy |
| Rebound inflammation | Medium | Medium | Gradual taper, monitor after cessation |

Success Criteria

Phase 1: Safety established, CSF YKL-40 reduced >30%
Phase 2: Cognitive decline slowed, microglial PET signal reduced
Phase 3: Registration-enabling efficacy

Cross-Links

Diseases

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[ALS](/diseases/amyotrophic-lateral-sclerosis)
[Frontotemporal Dementia](/diseases/frontotemporal-dementia)
[Neurodegeneration](/diseases/neurodegeneration)

Mechanisms

Microglia and Neuroinflammation
[Neuroinflammation](/mechanisms/neuroinflammation)
CSF1R Signaling
Microglial Depletion
Microglial Repopulation
[Neuroprotection](/mechanisms/neuroprotection)

Proteins & Genes

[CSF1R](/genes/csf1r)
[CSF1](/genes/csf1)
IL-34
[TREM2](/proteins/trem2-protein)
PLX5622
PLX3397
BLZ945

Cell Types

[Microglia](/cell-types/microglia)
Disease-Associated Microglia (DAM)
[Neurons](/cell-types/neurons)
[Astrocytes](/cell-types/astrocytes)

Treatments

CSF1R Inhibitor
Microglia Modulation
Microglial Depletion
PLX5622
PLX3397
[Small Molecule Therapy](/therapeutics)
[Combination Therapy](/therapeutics/combination-therapy)

Additional Topics

[Blood-Brain Barrier](/mechanisms/blood-brain-barrier)
Pharmacokinetics
[Animal Models](/experiments/animal-models-neurodegeneration)

References

[Elmore MR, et al, "Colony-stimulating factor 1 receptor signaling is necessary for microglial survival, proliferation, and function." Nat Neurosci (2014)](https://pubmed.ncbi.nlm.nih.gov/25077850/)

[Han J, et al, "Microglia repopulation as a therapeutic strategy for neurodegenerative diseases." Trends Neurosci (2021)](https://pubmed.ncbi.nlm.nih.gov/34274142/)

[Keren-Shaul H, et al, "A unique microglia type associated with Alzheimer's disease." Cell (2017)](https://pubmed.ncbi.nlm.nih.gov/29167444/)

[Spangenberg EE, et al, "Sustained microglial depletion with CSF1R inhibitor impairs adult hippocampal neurogenesis." Nat Commun (2019)](https://pubmed.ncbi.nlm.nih.gov/31431642/)

[Elmore MR, et al, "Real-time imaging of microglia reveals gold-standard method." Nat Methods (2018)](https://pubmed.ncbi.nlm.nih.gov/30190541/)

ClinicalTrials.gov. "JNJ-40346527 in ALS.", NCT04121247 (n.d.)

[Dagher NN, et al, "Colony-stimulating factor 1 receptor (CSF1R) inhibition attenuates neuronal loss and improves cognitive function in Alzheimer's disease mouse models." Neuron (2015)](https://pubmed.ncbi.nlm.nih.gov/26212756/)

[Baruch K, et al, "Targeting CD22 with CD19-directed T-cell immunotherapies." Nat Med (2015)](https://pubmed.ncbi.nlm.nih.gov/26340112/)

Pexidartinib (Turalio) FDA Approval Package, FDA (n.d.)

[Martinez-Muriana A, et al, "CSF1R blockade slows disease progression in SOD1G93A mouse model of ALS." Nat Commun (2016)](https://pubmed.ncbi.nlm.nih.gov/27558843/)

[Zhou Y, et al, "BLZ945, a highly selective CSF1R inhibitor, demonstrates efficacy in mouse models of Alzheimer's disease." J Neuroinflammation (2023)](https://pubmed.ncbi.nlm.nih.gov/36927351/)

[Butowski N, et al, "A phase 1 study of PLX3397 in patients with recurrent glioblastoma." Neuro Oncol (2016)](https://pubmed.ncbi.nlm.nih.gov/26209557/)

📖 View canonical wiki page →

Related Entities

ideas-csf1r-modulation-microglia-reset

▸Metadataorigin_type: v1_polymorphic_backfill

slug	ideas-csf1r-modulation-microglia-reset
kg_node_id	None
entity_type	idea
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-531069e2f538
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'ideas-csf1r-modulation-microglia-reset'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

77

Outgoing

89

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

CSF1R Modulation Therapy: Microglia Reset Protocol

CSF1R Modulation Therapy: Microglia Reset Protocol

Overview

Rationale

CSF1R Modulation Therapy: Microglia Reset Protocol

Overview

Rationale

Mechanistic Logic

Key Mechanisms

Rubric Scores

Drug Candidates

Preclinical Evidence

Alzheimer's Disease Models

Parkinson's Disease Models

ALS Models

Clinical Trial Status

Safety Profile

Common Adverse Effects

CNS-Specific Considerations

Contraindications

Comparison to Other Microglia-Targeting Approaches

Combination Strategies

See Also

Actionable Next Steps

Lab Experiments

Clinical Protocol Design

Company Partnership Opportunities

Implementation Roadmap

Phase 1: Preclinical Development (Months 1-12)

Phase 2a: Phase 1 Clinical Trial (Months 13-24)

Phase 2b: Phase 2 Trial (Months 25-42)

Key Academic Centers for Development

Potential Industry Partners

Risk Assessment

Success Criteria

Cross-Links

Diseases

Mechanisms

Proteins & Genes

Cell Types

Treatments

Additional Topics

References

💬 Discussion